Regulus Therapeutics Inc. with ticker code (RGLS) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The range between the high target price and low target price is between 1.5 and 0.5 and has a mean target at 1. With the stocks previous close at 1.3 this would imply there is a potential downside of -23.1%. The 50 day MA is 0.77 and the 200 moving average now moves to 0.69. The company has a market capitalisation of $90m. Find out more information at: http://www.regulusrx.com
The potential market cap would be $69m based on the market concensus.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
